(KP) can improve health-related quality of life. In the Netherlands, the incidence of KPs and KP revisions has increased, but health care costs related to these procedures over time and their determinants are unknown.
Conclusions:
These results underscore the increasing burden associated with severe knee OA, especially in younger age categories. Improved guidelines aimed at avoiding complications and revisions are required to counteract this trend. Background: While practical guidelines and recommendations play an important role in the treatment of RA, rheumatologists often tend to deviate from these guidelines (1) . This may result in disparity of quality of care among individual doctors and hospitals. To establish the best possible care, quality measures are needed. These aim to quantify the quality of the delivered care and will form the foundation of quality registries. Standardization of care processes in combination with public reporting of performance (by means of a quality registry) has been suggested to improve quality of care (2) . Objectives: To develop feasible quality indicators (QIs), endorsed by the different stakeholders of the Dutch Quality registry Rheumatoid Arthritis (DQRA). Methods: An expert group of 8 rheumatologists, 2 patient representatives and 1 healthcare insurer representative developed a minimal set of QIs via a Delphi-like procedure (3), endorsed by the Dutch Society for Rheumatology. Since October 2015, these QIs have been registered by rheumatologists and rheumatology nurses, once a year in 26 hospitals, along with a patient evaluation questionnaire regarding the received care. To determine whether it is feasible to collect these QIs in daily practice, retrospective data from three hospitals was obtained (hospital A (university), B and C (non-academic)). Feasibility was determined by evaluation of: 1. Completeness of registered data (figure 1) 2. Possibility to calculate disease activity categories (remission, low-high disease activity) 3. Possibility to calculate changes over time in disease activity categories 4. Extraction of data regarding (b)DMARD use Results: Selected QIs are: 1. Percentage of patients in a certain disease activity category 2. Percentage of patients using a certain (b)DMARD 3. Patient reported experience with received care Hospital B provided only data from one year (2014) and was not able to extract data on medication from their electronic record system. Background: Biotherapies such as subcutaneous tumour necrosis factor-alpha inhibitors (SC-TNFis) have transformed the management of rheumatoid diseases. The assessment of SC-TNFis non-persistence and its impact on medical resource utilization and costs are needed. Objectives: The objective was to assess the impact of non-persistence to subcutaneous TNF-alpha inhibitors on medical resource utilization and costs, for patients initiating treatment with an SC-TNFi in France. Background: Several studies documented the presence of cognitive dysfunction in different rheumatologic autoimmune diseases, but the absence of standard criteria of diagnostic and of an index with patients in which this dysfunction occurs, makes the mentioned studies often lead to divergent conclusions. Objectives: To evaluate the impact of four autoimmune diseases:Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc) and Ankylosing Spondylitis (AS) on patient cognition and to identify potential factors which lead to cognitive dysfunction occurrence in this diseases. Methods: This is a case-control study that included randomly selected patients with SLE, RA, SSc and AS from a University hospital and a matched control group. Data collected included: demographics, patients' education and specific data related to disease (duration, activity scores: DAS284v for RA patients, BASDAI in patients with AS, SLICC/SLEDAI for SLE patients and EUSTAR score/Rodnan score for SSc patients, damage indexes, organ involvement, treatment) and comorbidities. Cognition was assesed using MoCA Test (Montreal Cognitive Assessment The Test). The data were then processed using SPSS 23 version software. Results: The study group included 255 patients: 58 RA patients, 52 SLE, 70 SSc and 25 AS patients and 50 healthy matched controls. In all groups of patients, cognitive dysfunction prevalence was higher than control group (RA-64.98%, SLE -57.69%, SS -44.29%, AS -35.72% vs. 24% in the control group). The differences were statistically significant for the RA group (p=0.00), the SLE group (p=0.001), and the SS group (p=0.001). For the RA group none of the items analyzed (demographics, disease characteristic, patient' education) showed a significant correlation with cognitive dyfunction. The same lack of correlation was also noted in AS and SSc patients. For the SLE group the only variable analyzed with a significant impact statistically was the SLEDAI score over 12 (p=0.002). Also, this study did not find a significant statistically association between the presence of antiphospholipid syndrome. Cognitive dysfunction seems to be more frequent and severe in RA and SLE patients compared to AS patients (p=0.014, respectively p=0.05).
The results obtained in this study show that, indeed, cognitive dysfunction is an issue to be watched very carefully in patients with autoimmune diseases. The appearance of cognitive dysfunction has a negative impact on life quality of these patients, the pathophysiological mechanisms that contribute to it's appearance are intricate and difficult to isolate.
